Increased incidences of vaginal and invasive candidiasis, as well as premature births, place a heavy financial burden on the patient population and drive up the growth of market.
For instance, in 2017, the Centres for Disease Control and Prevention (CDC) reported that one of the most prevalent bloodstream infections in the United States was candidemia, a type of invasive candidiasis, with an average incidence of about 9 per 100,000 occurrences between 2013 and 2017.Additionally, according to the same source, invasive candidiasis accounted for 48% of hospitalisation for Candida infections in 2017 and around 84% of all healthcare cost, with an average hospitalisation cost of between US$ 64,723 and US$ 153,090.
The size of the global Candidiasis Market was estimated at US$ 873.8 million in 2017 and is anticipated to grow at a CAGR of 4.6% from 2018 to 2026.
1. Basilea Pharmaceutica Ltd.: A biopharmaceutical firm at the commercial stage, Basilea Pharmaceutica Ltd. is dedicated to finding, creating, and marketing medicines to treat patients with serious bacterial and fungal diseases. Germany and the UK both have active subsidiaries of the company. Established in 2000. Base of operations in Switzerland. SillaJen acquires the rights to the cancer product BAL0891, and Basilea improves its financial outlook.
2. Astellas Pharma Inc.: Pharmacies are sold all around the world by the drug manufacturer Astellas Pharma Inc. Japan generates the great bulk of the company's sales, followed by the Americas. A minor portion of Astellas' total sales come from royalties. Oncology, urology, and transplantation are its top three therapeutic specialties by sales composition. The company's long-term growth plan includes mergers and acquisitions. In order to expand its commercialization platforms, Astellas enters into strategic alliances and licencing agreements. Head office in Japan. Astellas Signs a Final Agreement to Purchase Iveric Bio.
3. Grupo Ferrer Internacional: Chemical and medicines producer. Prescription medications, medical supplies, vaccinations, consumer healthcare, fine chemicals, and other related products are among the company's offerings. Established in 1959. Spanish headquarters are in Barcelona.
4. S.A., Pacgen Life Science Corporation: A Canadian life science business is Pacgen Life Science Corp. Its main goal is to create a global commercial platform for the marketing and distribution of consumer health goods like Babycare, acne treatment, cosmetics, and personal care products, among others. In two reportable market areas, dental care and skin care, the firm sells its products under the trade names P113, DermaMed, DermaSoleil, and Deserving Health. Created in 2004. Headquarter location: Canada, Vancouver, British Columbia, V6C 3P6. The General Biologicals Corporation has acquired all of the Company's issued and outstanding common shares, with the exception of Pacgen Shares owned by GBC, its Executive Chairman, and affiliated companies, according to a statutory plan of arrangement that Pacgen Life Science Corporation completed under the Business Corporations Act.
5. Grupo Ferrer Internacional: Owners of an immunotherapeutic business that aims to shield patients from bacterial and fungal infections. The business creates preventive vaccines with recombinant albicans agglutinin-like sequence 3 (Als3) surface proteins that make it easier for pathogens to adhere to and invade human endothelial cells, lessening the severity of disease brought on by both bacterial and fungal pathogens and allowing patients to develop immunity before contracting the illness. Established in 2005. United States headquarters.
6. Cidara Therapeutics, Inc: Biotechnology firm Cidara Therapeutics Inc. Its main goal is to find, create, and market innovative anti-infectives for the treatment and eradication of disease. Rezafungin, a brand-new antifungal chemical from the business, belongs to the echinocandin class. Rezafungin is being developed as a first-line treatment and preventative measure for dangerous, invasive fungal infections that have a high fatality rate. There are also CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC among its other product candidates. Created in 2013. United States headquarters. In 2022, Melinta declared that it has purchased from Cidara the exclusive rights to market REZZAYO in the United States.
7. Pfizer, Inc: Pfizer Inc. is a pharmaceutical and biotechnology company based in America. It was founded in the year 1849. Pfizer manufactures and produces vaccines and medicine related to oncology, neurology, cardiology, and immunology. The corporation has produced various products that yield more than US$1 billion in annual revenue. The company ranked 64th on the Fortune 500 and 49th on the Forbes Global 2000. The headquarters are located in New York City, U.S. and the products manufactured are sold worldwide. The company was founded by Charles Pfizer and Charles F. Erhart. In 2022, the company acquired Arena Pharmaceuticals for US$ 6.7 Billion. In October 2022, Pfizer completed the acquisition Biohaven Pharma for US$ 11.6 Billion.
*Definition: Candidiasis is a fungal infection caused by a yeast called Candida.
